JAB X1800
Alternative Names: JAB-X1800Latest Information Update: 02 Aug 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action 5-nucleotidase inhibitors; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Jacobio Pharmaceuticals plans for clinical trial for Solid tumours
- 14 Apr 2023 Preclinical trials in Solid tumours in China (Parenteral)
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from preclinical trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)